the aid library

LIST OPTIONS

Filter

1526

Sort by:

Direction:

Download (706)

View PDF (1502)

Guidelines on hepatitis B and C testing
recommended

World Health Organization (WHO) (2017) C_WHO

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to recei... more

Download (715)

View PDF (1288)

A practical handbook on the pharmacovigilance of antiretroviral medicines

World Health Organization WHO (2013) C_WHO

This is a detailed manual giving a step by step approach to undertaking the pharmacovigilance of antiretrovirals. It is intended to be a source of practical advice for Pharmacovigilance Centres and health professionals involved in HIV/AIDS prevention and treatment programmes. A number of WHO publica... more

Download (1613)

View PDF (771)

IMAI district clinician manual: hospital care for adolescents and adults: guidelines for the management of illnesses with limited-resources. Vol. 2
recommended

World Health Organization WHO (2011) C_WHO

The manual is written for clinicians working at the district hospital (first-level referral care) who diagnose and manage sick adolescents and adults in resource constrained settings. It aims to support clinical reasoning, and to provide an effective clinical approach and protocols for the managemen... more

Download (854)

View PDF (1299)

Global report on psoriasis

World Health Organization WHO (2016) C_WHO

Psoriasis, which can involve the skin, nails and joints, is a chronic, painful, disfiguring and disabling noncommunicable disease (NCD) for which there is no cure. It negatively impacts on quality of life. Some of those who suffer from the disease develop chronic, inflammatory arthritis (psoriatic a... more

Download (4587)

View PDF (2666)

Guideline for Adverse Drug Events Monitoring (Pharmacovigilance), Ethiopia

Food, Medicine and Health care Administration and Control Authority of Ethiopia (FMHACA) (2014) C1

3rd edition

Download (764)

View PDF (1614)

WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses

World Health Organization (2012)

The Access to Controlled Medications Programme identified the development of treatment guidelines that cover the treatment of all types of pain as one of the core areas of focus for improving access to opioid analgesics. Such guidelines are interesting both for health-care professionals and policy-... more

Download (164)

View PDF (311)

Addressing comorbidity between mental disorders and major noncommunicable diseases

World Health Organization WHO; Regional Office for Europe (2017) C_WHO

Reduced healthy life expectancy due to the high burden of both mental ill health and noncommunicable diseases (NCDs) is a major public health concern in the European Region. The links between mental disorders and major NCDs are well established. In clinical practice, however, mental disorders in pa... more

Download (820)

View PDF (1710)

Management of MDR-TB: A field guide

Partners in Health, World Health Organization (2009) C_WHO

Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) increasingly occur in resource-constrained settings. In the context of a national response to MDR- and XDR-TB, health workers in TB clinics (in district hospitals and some accredited health centres) wil... more

Download (767)

View PDF (1082)

Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents

Lawrence Flick Memorial Tuberculosis Clinic, Philadelphia Tuberculosis Control Program (1998) C2

Download (138)

View PDF (189)

Remote psychological first aid during the COVID-19 outbreak

International Federation of Red Cross and Red Crescent Societies IFRC (2020) CC

Psychological first aid (PFA) is a method of helping people in distress so they feel calm and supported to cope better with their challenges. It is a way of assisting someone to manage their situation and make informed decisions. The basis of psychological first aid is caring about the person in dis... more

Download (115)

View PDF (154)

Remote Psychological First Aid during COVID-19 – May 2020

IFRC Reference Centre for Psychosocial Support IFRC Reference Centre for Psychosocial Support (2020) CC

Download (397)

View PDF (171)

National guideline for management of Non Communicable Diseases(NCDs)

Rwanda Biomedical Center Ministry of Health Rwanda (2016) CC

Non-Communicable Diseases (NCDs) are a worldwide epidemic. Particularly, the most common diseases - Cardiovascular diseases, Chronic Obstructive Pulmonary Diseases (COPD), Chronic Kidney Diseases, Cancer, Diabetes, injuries and disabilities, EMT, oral, eye g... more

Download (185)

View PDF (117)

Implementation Framework & Clinical Guidance for Viral Hepatitis Prevention & Treatment 2019

Ministry of Health, Zambia (2020) CC

The Zambia Population Based HIV impact assessment of 2016, reported the prevalence of viral hepatitis in Zambia as ranging between 5.6% among adults aged 15 to 59% in the general population, and 7.1% among HIV infected individuals. It is estimated that the majority of persons with chronic hepatitis ... more

Download (140)

View PDF (208)

11th Annual Meeting and First Virtual Meeting of the Intergovernmental Commission of the Amazonian Countries Initiative for the Surveillance and Control of Chagas Disease (AMCHA)

Pan American Health Organisation PAHO (2022) C_WHO

Due to the particular Amazonian situation of vectorial transmission based mostly on the wild cycle of Trypanosoma cruzi with diversity of triatomine vectors involved in effective transmission, and the variety of eco-epidemiological situations that facilitate such transmission, the countries of the A... more

Download (116)

View PDF (135)

Target product profile for a point-of-care diagnostic test for dermal leishmaniases - Control of Neglected Tropical Diseases

World Health Organization WHO (2022) C_WHO

Localized cutaneous leishmaniasis and its evolving forms (diffuse cutaneous leishmaniasis, mucosal leishmaniasis and cutaneous leishmaniasis recidivans), together with the sequela of visceral leishmaniasis (post-kala-azar dermal leishmaniasis), account for about one million cases of dermal leishmani... more

Download (104)

View PDF (785)

Diagnosis and Clinical Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas

Suárez, C., Nolder, D., García-Mingo, A. et al. Research and reports in tropical medicine (2022) CC

Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the South of the United States. It is an important cause of early mortality and morbidity, and it is associated with poverty and stigma. A third of the cases evolve into chronic... more

Download (177)

View PDF (190)

A systematic review of historical and current trends in Chagas disease

Álvarez-Hernández D., García-Rodríguez-Arana R., Ortiz-Hernández A. et al. Therapeutic advances in infectious disease (2021) CC

Chagas disease (CD) is caused by Trypanosoma cruzi. When acquired, the disease develops in stages. For diagnosis, laboratory confirmation is required, and an extensive assessment of the patient’s health should be performed. Treatment consists of the administration of trypanocidal drugs, which may... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (16)

View PDF (13)

Communicable and non-communicable diseases in Africa in 2021/22

World Health Organization Africa Region; WHO Africa World Health Organization Africa Region; WHO Africa (2023) C_WHO

This report is one of the first major products of the newly established Precision Public Health Metrics unit of the UCN cluster of the WHO Regional Office for Africa. The report presents national trends in communicable and non-communicable disease burden and control in the WHO African region. It tra... more

Download (34)

View PDF (29)

Standard Treatment Guidelines and Essential Medicines List for South Africa; Primary Healthcare Level 2020 Edition; Department of Health: Republic of South Africa

National Department of Health, South Africa National Department of Health, South Africa (2020) CC2

The "Primary Healthcare Standard Treatment Guidelines and Essential Medicines List" by the South African National Department of Health provides evidence-based guidelines for diagnosing and managing common medical conditions at the primary healthcare level. This document includes treatment protocols ... more

Guidelines on hepatitis B and C testing recommended

IMAI district clinician manual: hospital care for adolescents and adults: guidelines for the management of illnesses with limited-resources. Vol. 2 recommended

Guidelines on hepatitis B and C testing
recommended

IMAI district clinician manual: hospital care for adolescents and adults: guidelines for the management of illnesses with limited-resources. Vol. 2
recommended